Merck Q3 2026 profit after tax falls 50% to €450 million; Q3 2026 net sales rise 6% to €5.63 billion

Bitget2026/11/12 06:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Merck’s adjusted EBITDA pre rose to €1.68 billion in Q3 2026 from a year earlier.
Net sales climbed 6% year over year to €5.63 billion.
The group agreed to acquire Silence Therapeutics and divest its CDMO business to Lonza.
Raised FY26 guidance targets net sales of €21.5 billion–€21.9 billion and adjusted EBITDA pre of €6.2 billion–€6.4 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Merck Q3 2026 profit after tax falls 50% to €450 million; Q3 2026 net sales rise 6% to €5.63 billion

You may also like

Crypto prices